Yes, sertraline is FDA approved for PTSD in adults.
Sertraline is one of only two medications (along with paroxetine) that has received FDA approval specifically for the treatment of posttraumatic stress disorder in adults 1. This approval is based on two 12-week placebo-controlled trials demonstrating efficacy in adult outpatients meeting DSM-III-R criteria for PTSD 1.
FDA Approval Details
The FDA label explicitly states: "Sertraline Hydrochloride Oral Concentrate is indicated for the treatment of posttraumatic stress disorder in adults" 1. The approval was supported by:
- Two pivotal 12-week trials showing superiority over placebo on multiple outcome measures including the Clinician-Administered PTSD Scale (CAPS) and Impact of Event Scale (IES) 1
- Mean effective doses of 146-151 mg/day in completers 1
- Long-term efficacy data demonstrating maintenance of response for up to 28 weeks following initial 24-week treatment 1
Clinical Context and Positioning
While sertraline has FDA approval for PTSD, current treatment guidelines prioritize trauma-focused psychotherapy as first-line treatment 2. The 2024 VA/DoD Clinical Practice Guideline makes a strong recommendation for specific manualized psychotherapies (prolonged exposure, cognitive processing therapy, or EMDR) over pharmacotherapy 2.
When medication is indicated, sertraline represents one of three recommended options (along with paroxetine and venlafaxine) 2. The guideline specifically recommends these agents based on their evidence base, though notes that psychotherapy should be offered preferentially when available 2.
Important Prescribing Considerations
- Dosing: Initiate at 25 mg/day for the first week, then titrate to 50-200 mg/day based on response and tolerability 1
- Black box warning: All SSRIs carry warnings for suicidal thinking and behavior in patients up to age 24 years 1
- Gender considerations: Post-hoc analyses from the pivotal trials showed significant effects in women (76% of study population) but essentially no effect in the smaller number of men enrolled 1. The clinical significance of this finding remains unclear
- Discontinuation: Sertraline is associated with discontinuation syndrome; taper gradually when stopping 3
Limitations of Pharmacotherapy
The evidence supporting sertraline shows modest effect sizes compared to psychotherapy 4. Additionally:
- Relapse rates upon medication discontinuation are significant (26-52% depending on criteria used) 4
- Many patients continue to experience residual symptoms even with medication response 4
- Benzodiazepines should be avoided in PTSD treatment despite their common use, as they may worsen outcomes 2
Bottom line: Sertraline is FDA-approved and evidence-based for PTSD in adults, but should typically be considered after or alongside trauma-focused psychotherapy rather than as monotherapy, unless psychotherapy is unavailable or declined by the patient.